Browsing Tag
JAK inhibitors
3 posts
Lilly’s Olumiant moves closer to European approval for teen alopecia patients as CHMP issues positive opinion
Eli Lilly's Olumiant wins CHMP backing for adolescent alopecia areata with 42% response rates — EU approval imminent, U.S. decision due late 2026. Read the full analysis.
Incyte’s Opzelura delivers Phase 3b win in moderate adult atopic dermatitis patients
Incyte’s Opzelura cream shows strong Phase 3b results in adults with moderate atopic dermatitis. Find out what this could mean for EU filings and future growth.
Can AbbVie’s RINVOQ fill the biologics gap for IBD patients unsuitable for TNF therapy?
AbbVie gets FDA approval for broader RINVOQ use in IBD patients beyond TNF blockers. Find out how this impacts stock sentiment and investor expectations.